The Wonder Drug We Don't Know How to Use

I know how to save your life. After seven years of rigorous training, I can run a cardiac arrest, manage a ventilator, and reverse shock. I have become, by design, an expert in rescue. But next month, when I transition to primary care to manage the chronic diseases that cause these catastrophes, my confidence vanishes. It’s not because I don’t know the pharmacology. It’s because American medical training is designed to save you from dying, not to prevent you from getting sick.

I see this mismatch every week during the half-day per week dedicated to outpatient training. Ask any resident how GLP-1 drugs work—Ozempic, Wegovy, Mounjaro—and we can draw the molecular pathway. But ask what a patient should eat to keep their muscle while losing weight, and my precision vanishes. I have a generic handout and the words “try more protein.” Even my attendings hesitate. We’re managing a 2026 drug with a 1990 playbook.

This isn’t an accident. Hospitals, which employ most residents, profit from full beds. So our training focuses on the work that fills those beds. Sepsis. Shock. Trauma. The work that keeps beds empty is treated as a footnote.

Everyone knows the irony. Sustainable healthcare means keeping people out of hospitals. But hospitals don’t capture those savings. Insurers do, years later. So we keep training for rescue.

This economic reality leaves physicians unprepared. The failure isn’t unique to weight loss; our training routinely overlooks the complex counseling required for any chronic disease. GLP-1s just force the issue into the spotlight. These drugs stress-test a system that claims to value prevention but doesn’t train for it. Patients need real conversations about nutrition, side effects, and what happens when hunger returns. Instead, they get a checkbox: “Counseled on diet and exercise.” When they stop the drug because of side effects or cost, the weight will return. It is biology crashing into a system that never planned for success.

The drugs work. The system doesn’t.

These drugs are now central to managing chronic disease. But our training treats prevention as a footnote, and our incentives treat it as an expense.

We need a system where the education and the economics match the science. Without that change, we’ll keep handing patients a breakthrough drug and hoping they figure out the rest on their own.

Until residents are trained to prevent disease just as rigorously as we are trained to treat its collapse, we will remain experts in rescue and amateurs in care. The drugs are ready. The question is how we get there, and when.